{
    "nctId": "NCT00270491",
    "briefTitle": "Capecitabine Associated With Weekly Paclitaxel in Metastatic Breast Cancer.",
    "officialTitle": "A Multicenter Randomized Phase II Study Evaluating Tolerance and Efficacy of Capecitabine 5/7 Days With Weekly Paclitaxel Versus the Recommended Treatment Plan of Weekly Paclitaxel-capecitabine, in Patients With Metastatic Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 130,
    "primaryOutcomeMeasure": "tolerance of the patients in the both groups.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Femal patient aged \\> 18 years\n* Histologically proven breast adenocarcinoma\n* HER2 negative receptors\n* previously received first or second line chemotherapy for metastatic disease\n* previously treated with anthracycline and/or docetaxel in adjuvant and/or as first or second line therapy\n* presence of one or several evaluable metastatic lesion(s)\n* presence of at least one target lesion not previously irradiated\n* previously treated with hormonotherapy in adjuvant or in metastatic line (treatment will be ceased upon patient registration in the study)\n* ECOG Performance status \\< 2\n* adequate biological values\n* patient who has clearly given her consent by signing on informed consent form prior to participation\n\nExclusion Criteria:\n\n* patient previously treated with paclitaxel or capecitabine for metastatic breast cancer\n* patient with only local metastatic disease (with the exception of axillary lymph nodes)\n* active symptomatic brain metastasis\n* patient with an history of significant cardiovascular impairment (congestive heart failure\\> NYHA grade II, unstable angina or myocardial infraction within the past six months or serious cardiac arrhythmia)\n* peripheric neuropathy grade \u2265 2\n* history of another malignancy within past 5 years that could confound diagnosis or staging of breast cancer (with the exception of in situ cacinoma of the cervix or adequately treated basel cell carcinoma of the skin)\n* patient with any medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude her from participating in this study\n* patient with a known allergy to one or several of the study compounds\n* patients who may not be regularly available due to geographical, social or family reasons\n* history of renal, hepatic or metabolic pathology that could preclude with metabolism or elimination of the study product\n* deficiencies of the upper intestinal tract, malabsorption syndrome\n* patient who is pregnant, breast-feeding or using inadequate contraception",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}